Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide
Authors:
- Sabina SevcikovaSSSabina Sevcikova
- Ondrej SlabyOSOndrej Slaby
- Petra KaisarovaPKPetra Kaisarova
- Vladimir MaisnarVMVladimir Maisnar
- Miroslav PenkaMPMiroslav Penka
- Tomas PikaTPTomas Pika
- Ludek PourLPLudek Pour
- Jakub RadochaJRJakub Radocha
- Vlastimil ScudlaVSVlastimil Scudla
- Hana SvachovaHSHana Svachova
- Roman HajekRHRoman Hajek
- 1 October 2011
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (5) , 414-420
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Health
- Ministerstvo Školství, Mládeže a Tělovýchovy (NS10406, NS10408)
This publication has 23 references indexed in Scilit:
- Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytesJournal of Thrombosis and Haemostasis, 2009
- Risk stratification for cancer-associated venous thromboembolismBest Practice & Research Clinical Haematology, 2009
- Thrombosis associated with angiogenesis inhibitorsBest Practice & Research Clinical Haematology, 2009
- Tissue factor in cancerCurrent Opinion in Hematology, 2008
- The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging optionsJournal of Surgical Oncology, 2007
- Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With CancerJAMA, 2006
- Tissue factor as an effector of angiogenesis and tumor progression in hematological malignanciesLeukemia, 2006
- Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed MyelomaJournal of Clinical Oncology, 2002
- Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapyBlood, 2002
- Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapyBlood, 2002